" class="no-js "lang="en-US"> Exscientia Archives - Medtech Alert
Monday, June 17, 2024

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage

Exscientia today announced that Sumitomo Pharma plans to initiate a Phase 1 clinical study of […]

Exscientia Builds Automated Laboratories in Oxford to Expand Pipeline

Exscientia today announced the opening of a 21,000 square foot expansion of its facilities at […]

Exscientia Accelerates COVID-19 Drug Discovery Using AI

Exscientia has received a grant from the Bill & Melinda Gates Foundation and Gates Philanthropy […]

EQRx and Exscientia Enter Strategic Drug Creation, Development, and Commercialization Collaboration to Accelerate the Advancement of New World-Class Medicines

EQRx, a company committed to developing and delivering important new medicines to patients at radically […]

Exscientia Announces Second Molecule Created Using AI from Sumitomo Dainippon Pharma Collaboration to Enter Phase 1 Clinical Trial

Exscientia Ltd. (Headquarters: Oxford, UK; CEO: Andrew Hopkins) is pleased to acknowledge that Sumitomo Dainippon Pharma Co., […]

Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials

Exscientia, a leading artificial intelligence (AI)-driven pharmatech company, today announced the first AI-designed molecule for […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more